Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb:164:105402.
doi: 10.1016/j.phrs.2020.105402. Epub 2020 Dec 24.

Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19

Emilio Di Maria  1 , Paolo Martini  2 , Massimo Gennarelli  3
Affiliations
Comment

Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19

Emilio Di Maria et al. Pharmacol Res. 2021 Feb.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no declarations of interest.

Comment on

  • Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.
    Clementi N, Scagnolari C, D'Amore A, Palombi F, Criscuolo E, Frasca F, Pierangeli A, Mancini N, Antonelli G, Clementi M, Carpaneto A, Filippini A. Clementi N, et al. Pharmacol Res. 2021 Jan;163:105255. doi: 10.1016/j.phrs.2020.105255. Epub 2020 Oct 20. Pharmacol Res. 2021. PMID: 33096221 Free PMC article.

References

    1. Clementi N., Scagnolari C., D’Amore A., Palombi F., Criscuolo E., Frasca F., Pierangeli A., Mancini N., Antonelli G., Clementi M., Carpaneto A., Filippini A. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. Pharmacol. Res. 2020 - PMC - PubMed
    1. Pafumi I., Festa M., Papacci F., Lagostena L., Giunta C., Gutla V., Cornara L., Favia A., Palombi F., Gambale F., Filippini A., Carpaneto A. Naringenin impairs two-pore channel 2 activity and inhibits VEGF-induced angiogenesis. Sci. Rep. 2017;7(1):5121. - PMC - PubMed
    1. McKee D.L., Sternberg A., Stange U., Laufer S., Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol. Res. 2020;157 - PMC - PubMed
    1. Di Maria E., Latini A., Borgiani P., Novelli G. Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS and COVID-19): rapid systematic review and field synopsis. Hum. Genomics. 2020;14(1):30. - PMC - PubMed
    1. Ellinghaus D., Degenhardt F., Bujanda L., Buti M., Albillos A., Invernizzi P., et al. Genomewide association study of severe Covid-19 with respiratory failure. N. Engl. J. Med. 2020;383(16):1522–1534. - PMC - PubMed